Aadi Bioscience, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
Acuta Capital Partners and Anupam Dalal have reported a 9% beneficial ownership stake in Whitehawk Therapeutics following a private placement.
Avoro Capital Advisors disclosed a significant investment in Whitehawk Therapeutics through a $25 million private placement.
Neil Desai's beneficial ownership in Aadi Bioscience, Inc. has fallen to 4.9% after the company completed a private placement (PIPE) financing, issuing 21.6 million new shares.
SCHEDULE 13D/A: Shareholder Criticizes Aadi Bioscience Board for Rejecting Superior Buyout Offer and Pursuing Dilutive Financing
A significant shareholder, BML Investment Partners, L.P. and Braden M. Leonard, has reduced its stake in Aadi Bioscience, Inc. after criticizing the company's Board for rejecting a buyout offer of over $5 per share in favor of a dilutive $2.40 per share PIPE financing and a risky pre-clinical asset acquisition.
SCHEDULE 13D/A: Avoro Entities and Behzad Aghazadeh Boost Stake in Aadi Bioscience to 19.99% Following PIPE Financing
Avoro Capital Advisors, Avoro Ventures, and Behzad Aghazadeh have increased their beneficial ownership in Aadi Bioscience, Inc. to 19.99% of outstanding common stock following the closing of the 2024 PIPE Financing.
SCHEDULE 13D/A: Activist Investor Opposes Aadi Bioscience's Strategic Shift, Citing Rejected Acquisition Offer and Shareholder Dilution
An activist investor group, BML Investment Partners, L.P. and Braden M. Leonard, has filed an amended Schedule 13D, publicly opposing Aadi Bioscience, Inc.'s proposed strategic transactions, including an asset sale and significant share dilution, in favor of a previously rejected acquisition offer.
SCHEDULE 13D/A: Activist Investor Demands Aadi Bioscience Records Over Rejected Acquisition Bids and Dilutive Financing
Aadi Bioscience, Inc. faces a demand for books and records from activist investor BML Investment Partners, L.P. and Braden M. Leonard, who allege mismanagement, rejected favorable acquisition offers, and a highly dilutive financing deal that benefited insiders.
SCHEDULE 13D: Activist Investor BML Partners Opposes Aadi Bioscience's Proposed PIPE Deal, Citing Shareholder Disregard
BML Investment Partners, holding a 9.9% stake in Aadi Bioscience, has publicly expressed strong opposition to the company's proposed Private Investment in Public Equity (PIPE) deal and strategic direction, advocating for a full company sale instead.
Acuta Capital Partners, along with its affiliates, has disclosed a 7.8% ownership stake in Aadi Bioscience, Inc. following a private investment and board appointment.